Recombinant factor VIIa affects anastomotic patency of vascular grafts in a rabbit model  C. David Mazer, MD, FRCPC, Howard Leong-Poi, MD, FRCPC, Tejinder Chhina, MD, FRCPC, Zuhair Alfardan, MD, Harry Lapierre, MD, FRCSC, Zhilan Wang, MSc, Zane S. Jackson, MD, PhD, Beiping Qiang, MD, James Mahoney, MD, FRCSC, David Latter, MD, FRCSC, Gregory M.T. Hare, MD, PhD, FRCPC, Bradley H. Strauss, MD, FRCPC, Jerome Teitel, MD, FRCPC  The Journal of Thoracic and Cardiovascular Surgery  Volume 142, Issue 2, Pages 418-423 (August 2011) DOI: 10.1016/j.jtcvs.2010.11.020 Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Vein graft patency (defined as number of grafts patent/total number of grafts∗100) was significantly reduced in a dose-dependent fashion after rFVIIa. ∗P < .05 compared with placebo. †P < .05 compared with 20 μ/kg. ‡P < .05 compared with 90 μ/kg. CI, 95% Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 418-423DOI: (10.1016/j.jtcvs.2010.11.020) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Plasma factor VII activity levels increased significantly after 1 of 3 doses of rFVIIa. ∗P < .05 compared with placebo at the same time point. †P < .05 compared with 20 μg/kg and 90 μg/kg at the same time point. ‡P < .05 compared with baseline value. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 418-423DOI: (10.1016/j.jtcvs.2010.11.020) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions